Answers are grounded in this paper and cite their sources.
In vitro study demonstrates high-affinity single-domain antibodies targeting active Rap1 in platelets, highlighting a new platform to monitor platelet activation.
Background: Rap1 is critical for platelet activation, functioning as a key node of the platelet activation pathways. Objectives: This study aimed to develop VHH-Fc (minibodies) against Rap1 for the purpose to quantify active Rap1 levels in platelets. Methods: We have produced the first generation of VHHs against active Rap1 through a series of negative and positive screenings of a synthetic phage display library, utilizing both inactive and active Rap1B. We performed random mutagenesis, followed by yeast 2-hybrid screening to optimize variants. Results: of 4.4 nM and showed enhanced capacity to capture active GTP-bound Rap1 compared with the original VHH-Fc. Additionally, it was able to detect overexpressed active Rap1B G12V in HeLa cells. An ELISA setup combining VHH-Fc B14 and a commercial monoclonal antibody targeting total Rap1 was highly effective in detecting both GTPγS-bound Rap1 and endogenous active Rap1 in platelets. Conclusion: This study identifies, that accurately capture active Rap1 in platelets, thereby establishing them as promising tools for future research. We also developed a reliable ELISA test that can facilitate clinical studies to monitor platelet Rap1 activation in various medical contexts.
No takes yet. Share an insight, caveat, or question.
Alessi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: